CXCR2 and cancer: Due to the significant protumor functions of CXCR2, CXCR2 inhibitors have been evaluated in many clinical trials for treating cancers, as summarized in recent reviews.[33] The effectiveness of inhibiting CXCR2 in our model suggests that targeting the mechanism that facilitates MDSC recruitment would provide better therapeutic benefits for PDAC patients receiving AB680 treatment.